Stock Track | Nektar Therapeutics Plummets 5.07% Intraday Following Securities Class Action Lawsuit

Stock Track

03/13

Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday.

The decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges that Nektar made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial for alopecia areata treatment.

The legal action seeks damages for investors who purchased Nektar securities between February 26, 2025 and December 15, 2025, alleging violations of securities laws. This development creates uncertainty around the company's clinical trial disclosures and potential legal liabilities.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1178275171"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178275171\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178275171?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 00:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178275171","market":"sg","top_or_hot":-1,"title":"Stock Track | Nektar Therapeutics Plummets 5.07% Intraday Following Securities Class Action Lawsuit","media":"Stock Track","content":"<p>Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday.</p>\n<p>The decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges that Nektar made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial for alopecia areata treatment.</p>\n<p>The legal action seeks damages for investors who purchased Nektar securities between February 26, 2025 and December 15, 2025, alleging violations of securities laws. This development creates uncertainty around the company's clinical trial disclosures and potential legal liabilities.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Nektar Therapeutics Plummets 5.07% Intraday Following Securities Class Action Lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Nektar Therapeutics Plummets 5.07% Intraday Following Securities Class Action Lawsuit\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-03-13 00:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday.</p>\n<p>The decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges that Nektar made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial for alopecia areata treatment.</p>\n<p>The legal action seeks damages for investors who purchased Nektar securities between February 26, 2025 and December 15, 2025, alleging violations of securities laws. This development creates uncertainty around the company's clinical trial disclosures and potential legal liabilities.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTR","symbol_name":"內克塔治療","start_time":0,"source_url":"","article_id":"1178275171","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178275171","pubTimestamp":1773331959,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday. The decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKTR":"内克塔治疗"},"translate_title":"个股追踪|Nektar Therapeutics遭证券集体诉讼盘中暴跌5.07%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1},"content_text":"Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday.\nThe decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges that Nektar made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial for alopecia areata treatment.\nThe legal action seeks damages for investors who purchased Nektar securities between February 26, 2025 and December 15, 2025, alleging violations of securities laws. This development creates uncertainty around the company's clinical trial disclosures and potential legal liabilities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}